Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | LSS | P48449 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013863 | 0.89 | MAPT (0.50) | RAB9AKDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL18356861 | 0.85 | KDM4E (0.46) | RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17731988 | 0.85 | KDM4E (0.46) | RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29135410 | 0.85 | HDAC8 (0.49) | HDAC8GAAHDAC1CA12CA1 | |
| SCHEMBL712992 | 0.85 | HDAC1 (0.59) | HDAC8HDAC1HDAC2 | |
| SCHEMBL14544471 | 0.85 | HDAC1 (0.59) | HDAC8HDAC1HDAC2 | |
| SCHEMBL14883463 | 0.83 | HDAC1 (0.51) | HDAC8LSSGAARAB9AHDAC1 | |
| SCHEMBL22105970 | 0.82 | HDAC8 (0.46) | HDAC8GAAHDAC1CA12CA1 | |
| SCHEMBL25258003 | 0.82 | HDAC8 (0.41) | HDAC8CA12CA1CA2CA9 | |
| SCHEMBL22029387 | 0.81 | CA12 (0.68) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20180106812-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-9547008-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| US-20160025735-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-01-28 | — | — | US | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8969509-B2 | Signal amplified biological detection with conjugated polymers | SIRIGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20120252986-A1 | SIGNAL AMPLIFIED BIOLOGICAL DETECTION WITH CONJUGATED POLYMERS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-10-04 | — | — | US | disclosed |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | HDAC8 4313/4885LSS 4832/4885GAA 2099/4885 |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | HDAC8 4313/4885LSS 4832/4885GAA 2099/4885 |
| US-20180106812-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | HDAC8 4313/4885LSS 4832/4885GAA 2099/4885 |
| US-20110256549-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | HDAC8 4313/4885LSS 4832/4885GAA 2099/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | HDAC8 1676/4885LSS 2397/4885GAA 694/4885 |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | HDAC8 4313/4885LSS 4832/4885GAA 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.